Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in mice

Coxsackievirus A6 (CA6) has recently emerged as the predominant pathogen of hand, foot and mouth disease (HFMD), causing significant morbidity in children and adults. The increasing prevalence of CA6 infection and its associated disease burden underscore the need for effective CA6 vaccines. However,...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral research 2016-08, Vol.132, p.165-169
Main Authors: Zhou, Yu, Shen, Chaoyun, Zhang, Chao, Zhang, Wei, Wang, Lili, Lan, Ke, Liu, Qingwei, Huang, Zhong
Format: Article
Language:English
Subjects:
Animals
Antibodies, Neutralizing - blood
Antibodies, Neutralizing - immunology
Antibodies, Viral - blood
Antibodies, Viral - immunology
Coxsackievirus
Coxsackievirus A6
Coxsackievirus Infections - immunology
Coxsackievirus Infections - prevention & control
Disease Models, Animal
Enterovirus A, Human - immunology
Immunization
Mice
Neutralization Tests
Pichia pastoris
Recombinant Proteins - genetics
Recombinant Proteins - immunology
Recombinant Proteins - metabolism
Vaccine
Vaccines, Virus-Like Particle - immunology
Viral Structural Proteins - genetics
Viral Structural Proteins - immunology
Viral Structural Proteins - metabolism
Viral Vaccines - immunology
Virus-like particle
Yeasts - genetics
Yeasts - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Coxsackievirus A6 (CA6) has recently emerged as the predominant pathogen of hand, foot and mouth disease (HFMD), causing significant morbidity in children and adults. The increasing prevalence of CA6 infection and its associated disease burden underscore the need for effective CA6 vaccines. However, CA6 grows poorly in cultured cells, making it difficult to develop inactivated whole-virus or live attenuated vaccines. Here we report the development of a recombinant virus-like particle (VLP) based CA6 vaccine. CA6 VLPs were produced in Pichia pastoris yeast transformed with a vector encoding both P1 and 3CD proteins of CA6. Immunization with CA6 VLPs elicited CA6-specific serum antibodies in mice. Passive transfer of anti-VLP antisera protected recipient mice against lethal CA6 challenge. Collectively, these results demonstrate that CA6 VLPs represent a viable CA6 vaccine candidate which warrants further preclinical and clinical development. •Recombinant VLPs of CA6 were produced in Pichia pastoris yeast.•Immunization with the VLPs induced CA6-specific antibodies in mice.•Passive transfer of anti-VLP antisera protected recipient mice against CA6 challenge.
ISSN:0166-3542
1872-9096
DOI:10.1016/j.antiviral.2016.06.004